Skip to main content
    C

    CG Oncology, Inc. Common stock (CGON)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $84.78
    +10.38 (+13.95%)

    Market Cap: $6.65B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    CG Oncology, Inc. Common stock (CGON) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to CG Oncology, Inc. Common stock are Cogent Biosciences (COGT), TG Therapeutics (TGTX) and Tango Therapeutics (TNGX). By market cap, CG Oncology, Inc. Common stock ranks 7th of the 13 companies on this page; Vaxcyte (PCVX) is the largest at $10.03B. The median P/E of the 3 companies with a P/E is 87.2x.

    Peer Comparison

    CGON's ROIC of -21.1% is above the peer median of -66.0%, and its revenue growth of -3.7% is below the median of 16.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    CG Oncology, Inc. Common stock (CGON)$6.65BN/AN/A0.0%-21.1%-3.7%0.00%
    Cogent Biosciences Inc (COGT)$4.97BN/AN/A0.0%-43.4%-100.0%0.00%
    TG Therapeutics Inc (TGTX)$9.75B87.2x11.1x11.8%11.0%60.7%0.00%
    Tango Therapeutics Inc (TNGX)$4.32BN/AN/A0.0%N/A-100.0%0.00%
    Cytokinetics Inc (CYTK)$7.82BN/A65.3x0.0%-66.0%2357.0%0.00%
    Erasca Inc (ERAS)$5.50BN/AN/A0.0%N/A0.0%0.00%
    Abivax SA American Depositary Shares (ABVX)$7.67BN/AN/A0.0%-159.6%-6.8%0.00%
    Legend Biotech Corp (LEGN)$3.39B266.5x2.3x-0.0%N/A32.0%0.00%
    Immunovant Inc (IMVT)$7.07BN/AN/A0.0%N/A0.0%0.00%
    Iovance Biotherapeutics Inc (IOVA)$3.59BN/A9.1x-58.2%N/A80.1%0.00%
    Immunitybio Inc (IBRX)$6.40BN/A30.3x0.0%-780.5%52.3%0.00%
    Vaxcyte Inc (PCVX)$10.03BN/AN/A0.0%N/A0.0%0.00%
    Protagonist Therapeutics Inc (PTGX)$8.55B27.7x15.8x62.0%N/A5724.0%0.00%
    Peer median$6.74B87.2x13.4x0.0%-66.0%16.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to CG Oncology, Inc. Common stock, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Cogent Biosciences Inc (COGT)
    Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies to treat genetically defined diseases.
    COGT competitors
    TG Therapeutics Inc (TGTX)
    TG Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the acquisition, development...
    TGTX competitors
    Tango Therapeutics Inc (TNGX)
    Tango Therapeutics Inc. is a leading clinical-stage biotechnology firm at the forefront of cancer treatment innovation...
    TNGX competitors
    Cytokinetics Inc (CYTK)
    Cytokinetics, Incorporated, an advanced stage biopharmaceutical company, focuses on discovering...
    CYTK competitors
    Erasca Inc (ERAS)
    Erasca Inc. is a pioneering biopharmaceutical firm specializing in the development of targeted therapies for genetically defined cancers...
    ERAS competitors
    Abivax SA American Depositary Shares (ABVX)
    Abivax SA is a clinical-stage biotechnology firm focused on pioneering immunotherapies for chronic inflammatory diseases and viral infections.
    ABVX competitors
    Legend Biotech Corp (LEGN)
    Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology...
    LEGN competitors
    Immunovant Inc (IMVT)
    Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases.
    IMVT competitors
    Iovance Biotherapeutics Inc (IOVA)
    Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness...
    IOVA competitors
    Immunitybio Inc (IBRX)
    ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to fight multiple types of tumors without the use of high-dose...
    IBRX competitors
    Vaxcyte Inc (PCVX)
    Vaxcyte, Inc., a pre-clinical biotech vaccine company, develops novel vaccines to prevent or treat infectious diseases globally.
    PCVX competitors
    Protagonist Therapeutics Inc (PTGX)
    Protagonist Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops peptide-based therapeutic drugs to address unmet medical...
    PTGX competitors

    Frequently Asked Questions About CGON

    Who are CG Oncology, Inc. Common stock's main competitors?

    The companies most similar to CG Oncology, Inc. Common stock include Cogent Biosciences (COGT), TG Therapeutics (TGTX), Tango Therapeutics (TNGX), Cytokinetics (CYTK) and Erasca (ERAS), listed from the closest match.

    Who is CG Oncology, Inc. Common stock's biggest competitor?

    Vaxcyte (PCVX) is the largest of the similar companies at $10.03B; Cogent Biosciences (COGT) is the closest match by business profile, size, sector and industry.

    How does CGON stock compare with its competitors?

    CGON's net margin is 0.0% against a peer median of 0.0%.

    Which of CG Oncology, Inc. Common stock's competitors pays a higher dividend?

    CG Oncology, Inc. Common stock pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is CG Oncology, Inc. Common stock bigger than its competitors?

    No. CG Oncology, Inc. Common stock is 7th by market cap among the 13 companies on this page; the largest is Vaxcyte (PCVX) at $10.03B.